Most CRISPR-Cas9 screens utilize cancer cell lines and focus on CD8+ T cells, thereby providing no insights into clinical ICI relapse caused by defects in responsiveness to other cytolytic immune cell types or immune-cell trafficking. The gene discussed is CD8A; the disease is cancer.